de Marcellus, Charles; Tauziede-Espariat, Arnault; Cuinet, Aurelie; Pasqualini, Claudia; Robert, Matthieu P.; Beccaria, Kevin; Puget, Stephanie; Boddaert, Nathalie; Figarella-Branger, Dominique; De Carli, Emilie; Bourdeaut, Franck; Leblond, Pierre; Fouyssac, Fanny; Andre, Nicolas; Bertozzi, Anne I.; Butel, Thibaut; Dufour, Christelle; Valteau-Couanet, Dominique; Varlet, Pascale; Grill, Jacques published the artcile< The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients>, Quality Control of 112-63-0, the main research area is irinotecan bevacizumab anticancer agent KIAA1549 low grade glioma children; Bevacizumab; Children; Irinotecan; Low grade glioma.
At least half of children with low-grade glioma (LGG) treated with first line chemotherapy experience a relapse/progression and may therefore need a second-line chemotherapy. Irinotecan-bevacizumab has been recommended in this setting in France after encouraging results of pilot studies. We performed a retrospective anal. to define the efficacy, toxicity and predictors for response to the combination on a larger cohort. We reviewed the files from children < 19 years of age with progressive or refractory LGG treated between 2009 and 2016 in 7 French centers with this combination. In 72 patients (median age 7.8 years [range 1-19]) received a median of 16 courses (range 3-30). The median duration of treatment was 9 mo (range 1.4-16.2). 96% of patients experienced at least disease stabilization. The 6-mo and 2-yr progression-free survivals (PFS) were 91.7% [IC 95% 85.5-98.3] and 38.2% [IC 95% 28.2-51.8] resp. No progression occurred after treatment in 18 patients with a median follow-up of 35.6 mo (range 7.6-75.9 mo). Younger patients had a worse PFS (p = 0.005). Prior chemoresistance, NF1 status, duration of treatment, histopathol. or radiol. response did not predict response. The most frequent toxicities related to bevacizumab included grades 1-2 proteinuria in 21, epistaxis in 10, fatigue in 12 and hypertension in 8 while gastro-intestinal toxicity was the most frequent side effect related to irinotecan. Bevacizumab-irinotecan has the potential of disease control clin. and radiog. in children with recurrent LGG whatever their previous characteristics; in many cases however these responses are not sustained, especially in younger children. Journal of Neuro-Oncology published new progress about Aging, animal. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Quality Control of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics